Indica Labs
The Diagnostics & Research Institute for Pathology at the Medical University of Graz, a leader in personalised patient care and one of the largest hospitals in Austria, has selected the HALO AP digital pathology platform from Indica Labs to deliver primary diagnostics. The enterprise digital pathology platform was selected alongside Aperio GT 450 scanners from Leica Biosystems for quality, performance, functionality, and usability.
The user interface of HALO AP, localised in German, provides pathologists with an integrated view of each case.
Trusted by hospitals, pharma companies, and CROs alike according to the company, HALO AP supports primary diagnosis with integrated AI-enabled workflows, streamlines second opinion requests and consults, supports research pipelines, and manages clinical trials within a unified platform.
The Medical University of Graz anticipates reporting on ~400,000 glass slides generated annually by their institute beginning in January of 2025. With a large team of 30 pathologists, HALO AP will be integral to streamlining diagnostic workflows with its built-in suite of advanced tools and features. The Institute plans to take advantage of support for the DICOM file format to ensure that all digitised data is easily accessible for current and future research. In addition, HALO AP will be integrated with the PAS Xanthos laboratory information system from PROGRAMMIERFABRIK GmbH that is currently deployed at the university hospital.
Read more: Indica Labs receives first FDA clearance for HALO AP Dx digital pathology platform
"The selection of the HALO AP platform from Indica Labs represents a huge advance in our digital pathology capabilities," says Prof. Peter Regitnig from Med Uni Graz. "HALO AP's user-friendly interface greatly enhances our ability to interpret complex morphological features. Digital pathology is not only streamlining diagnostic workflows but also laying the essential groundwork for AI-driven analysis. This integration marks a significant step toward more accurate, efficient, and data-driven pathology practices. By embracing these technologies, we are positioning ourselves at the forefront of the next generation in medical diagnostics."
In addition to advancing diagnostic workflows, the Medical University of Graz plans to digitise tumour boards with HALO AP and will leverage annotated digital training sets created within the platform to enhance the education of medical students and resident pathologists.
"We're delighted that the prestigious Medical University of Graz has selected HALO AP to deliver precision medicine to their community," commented Steven Hashagen, CEO of Indica Labs. "With the ability to integrate any AI algorithm into HALO AP and deploy it for diagnostics, the Diagnostics & Research Institute for Pathology is well positioned for future expansion of their workflows."
HALO AP is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.
